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 ABSTRACT 
 Background  Rheumatoid arthritis (RA) can be divided 
into two major subsets based on the presence or 
absence of antibodies to citrullinated peptide antigens 
(ACPA). Until now, data from genome-wide association 
studies (GWAS) have only been published from ACPA-
positive subsets of RA or from studies that have not 
separated the two subsets. The aim of the current study 
is to provide and compare GWAS data for both subsets. 
 Methods and results  GWAS using the Illumina 300K 
chip was performed for 774 ACPA-negative patients 
with RA, 1147 ACPA-positive patients with RA and 1079 
controls from the Swedish population-based case–
control study EIRA. Imputation was performed which 
allowed comparisons using 1 723 056 single nucleotide 
polymorphisms (SNPs). No SNP achieved genome-
wide signifi cance (2.9 × 10 –8 ) in the comparison 
between ACPA-negative RA and controls. A case–case 
association study was then performed between ACPA-
negative and ACPA-positive RA groups. The major 
difference in this analysis was in the HLA region where 
768 HLA SNPs passed the threshold for genome-wide 
signifi cance whereas additional contrasting SNPs did 
not reach genome-wide signifi cance. However, one 
SNP close to the  RPS12P4 locus in chromosome 2 
reached a p value of 2 × 10 6 and this locus can thus be 
considered as a tentative candidate locus for ACPA-
negative RA. 
 Conclusions  ACPA-positive and ACPA-negative RA display 
signifi cant risk allele frequency differences which are mainly 
confi ned to the HLA region. The data provide further support 
for distinct genetic aetiologies of RA subsets and emphasise 
the need to consider them separately in genetic as well as 
functional studies of this disease. 
 INTRODUCTION 
 Rheumatoid arthritis (RA) is a common infl amma-
tory joint disease caused by a complex interplay of 
genetic variants and environmental exposures.  1  –  3  
Disease outcomes in RA are highly variable, and 
the presence or absence of antibodies to citrulli-
nated peptide antigens (ACPA) has proved to be 
one of the best clinical predictors of the severity 
of disease course.  4    5  In addition, ACPA-positive 
patients with unspecifi ed arthritis respond differ-
ently from ACPA-negative patients with RA to 
early methotrexate therapy.  6  
 In recent years a number of candidate genes have 
been shown to associate differently with ACPA-
positive and ACPA-negative RA. Several genetic 
variants within the HLA region,  specifi cally the 
shared epitope-containing HLA-DRB1 alleles,  7  –  9  
PTPN22 alleles,  10    11  as well as a variant in the 
C5-TRAF1 region,  12    13  TNFAIP3,  14    15  CD40, CCL21 
and many other loci  16    17  have been shown to asso-
ciate with ACPA-positive RA but have not been 
tested for ACPA-negative RA. By contrast, varia-
tions in IRF5  18  and C-type  lectin genes  19  appear to 
be associated with ACPA-negative RA. Association 
of ACPA-negative disease with HLA-DRB1*03 hap-
lotype was  previously suggested  20    21  but has not 
been replicated in a larger study.  22  In at least one 
study  23  an indication for an association of PTPN22 
marker with ACPA-negative RA was presented 
based on 65 cases of RA. On the other hand, STAT4 
variant has been shown in a meta-analysis to be a 
risk factor for both  subgroups of RA.  24  Smoking is 
the only environmental risk factor unambiguously 
associated with the risk of RA, but it too appears to 
affect risk only for ACPA-positive patients.  8  
 These data on different risk factors for ACPA-
positive and ACPA-negative RA have been used to 
propose a new aetiological model for ACPA-positive 
RA, whereas no such model yet exists for ACPA-
negative disease.  18    25    26  A major implication of these 
observations is that genetic and immunological stud-
ies of RA should consider this heterogeneity of RA. 
 So far, the most powerful technique to analyse 
the effects of genetic variation on disease suscepti-
bility—that is, the genome-wide association study 
(GWAS)—has not addressed this heterogeneity and 
genome-wide data published on RA to date have 
either considered ACPA-positive disease alone  13    17    27  
or grouped both subtypes together.  14    28  
 In order to provide a more complete pic-
ture of genetic risk factors for RA, we have per-
formed genome-wide association analyses in 
both RA subsets in two different collections of 
RA cases and controls defi ned by ACPA sta-
tus (Swedish Epidemiological Investigation of 
Rheumatoid Arthritis (EIRA) and North American 
RA Consortium (NARAC)), and in data from 
the Wellcome Trust Case–Control Consortium 
(WTCCC) which contains patients from both sub-
sets but where subdivision according to ACPA sta-
tus has not yet been performed. 
 METHODS 
 Subjects 
 EIRA is a population-based case–control study 
enrolling  incident (predominantly <1 year after 
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 RESULTS 
 GWAS of ACPA-negative RA 
 We conducted a GWAS for ACPA-negative patients with RA 
with 774 cases and 1079 controls selected from the EIRA study. 
Both genotyped and imputed single nucleotide  polymorphisms 
(SNPs) were included in the analysis. No single SNP reached 
genome-wide signifi cance ( fi gure 2 ). A Q-Q plot for observed 
versus expected p values is shown in  fi gure 3A and shows no 
signifi cant deviation from the expected distribution. As shown 
in  table 1 , fi ve SNPs from three genetic loci had p  values <10 −5 . 
One out of fi ve was not associated with ACPA-positive RA 
while the other four (from two independent loci at  chromosome 
7) had only nominal association. These results indicate little or 
no overlap between the two RA subgroups for the fi ve tenta-
tive SNPs that may associate with ACPA-negative RA in this 
GWAS. 
 Owing to our inability to identify any additional appro-
priately-sized case–control studies of ACPA-negative RA, we 
have so far been unable to replicate our fi ndings for ACPA-
negative RA. 
 GWAS of ACPA-positive RA 
 We have previously reported GWAS data on ACPA-positive 
RA based on a fraction of the EIRA study in combination 
with NARAC.  13  In addition to the previously used 627 ACPA-
positive RA cases and 641 controls from Sweden, we now 
selected 520 new ACPA-positive RA cases and 438 controls 
from the EIRA study for extension of the GWAS for ACPA-
positive RA. Because all cases and controls were taken from 
the same study population, we combined all EIRA samples 
into a single analysis which included both genotyped and 
imputed SNPs. The diagram of genome-wide association for 
this analysis is shown in  fi gures 4 and  5 and Q-Q plots are 
shown in  fi gure 3B . Out of 1 723 056 analysed SNPs, we found 
clinical onset) cases of RA. The study base comprises residents 
aged 18–70 years in a geographically-defi ned area in the cen-
tral and  southern parts of Sweden. Details of the study design 
have been reported elsewhere.  8    29    30  For each case a control was 
 randomly selected from the study base by matching age, sex 
and residential area. For the present study we selected 3176 
 individuals (829 ACPA-negative cases of RA, 1218 ACPA-
positive cases of RA and 1129 controls) for genome-wide geno-
typing. Informed consent was obtained from all participants and 
the ethical review board at the Karolinska Institutet approved 
the study. A portion of the data was included in a  previously 
 published GWAS of ACPA-positive RA  13  (see table 1 in online 
supplement), but here we enlarge the GWAS dataset for ACPA-
positive patients with RA and controls and include genome-
wide data on ACPA-negative patients for the fi rst time. 
 NARAC provided genotypes for 889 ACPA-positive patients 
and 1232 controls. The patients of self-reported white ancestry 
were recruited as prevalent (69.6%) or incident RA cases from 
several sites throughout North America. Nearly half of the cases 
(51.1%) reported a positive family history.  13  Control subjects 
were selected on the basis of similar self-reported ancestry from 
20 000 persons who were part of the New York Cancer Project. 
Written informed consent was obtained from all subjects who 
provided blood samples in accordance with protocols approved 
by the local institutional review boards. 
 The British RA population comprised 1860 patients and 
3000 controls. Recruitment procedures have been described pre-
viously, together with frequencies of genetic variations.  28  
 Demographic characteristics of patients and controls and 
the study logistics are shown in table 1 in the online supple-
ment and in  fi gure 1 where corresponding numbers after qual-
ity control procedures (see below) are shown. Genotyping, 
serological analysis and statistical evaluation are shown in the 
online supplement. 
 Figure 1  Work fl ow for genome-wide analysis (GWAS) of two subgroups of rheumatoid arthritis (RA). Three different Caucasian study populations 
represented in different colours (blue, green and red: Swedish, US, UK). Selection of data from previously published studies indicated by dashed 
rectangles with subsequent reference. Difference in sums is due to QC procedures at each stage of analysis. ACPA, antibodies to citrullinated peptide 
antigens. 
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1.96, p=9.77E-09). After relaxing the threshold for signifi cance 
up to 10 −6 , an additional 196 SNPs were found to be signifi cant 
from the HLA locus and seven non-HLA SNPs from the cluster 
of a ‘gene desert’ at chromosome 13 (see table 2 in online sup-
plement). These seven SNPs are all in a recombination block 
according to HapMap data.  31  
719 SNPs which passed a genome-wide signifi cance thresh-
old (see table 2 in online supplement). Of note, 718 of these 
SNPs were located within the HLA locus at chromosome 6 
with physical positions between 31 279 236 and 33 164 413 
(1 885 177 bp). A single non-HLA SNP rs2476601 was from 
 PTPN22 gene at chromosome 1 with OR 1.66 (95% CI 1.40 to 
 Figure 2  Probability plot for association with ACPA-negative rheumatoid arthritis (774 cases) versus 1079 controls, λ GC = 1.0132 based on 
1 723 056 single nucleotide polymorphisms. ACPA, antibodies to citrullinated peptide antigens. 
 Table 1  Characteristics of the top associated SNPs from GWAS of ACPA-negative RA versus controls 
 Reference 
sequence  Chromosome  Closest gene  Minor allele *
 ACPA-negative RA versus controls  ACPA-positive RA versus controls 
 Allelic counts 
for cases 
 Allelic counts 
for controls  OR (95% CI)  p Value† 
 Allelic counts 
for cases 
 Allelic counts 
for controls  p Value† 
rs4305317 2  RPS12P4 T 384/1132 691/1403 0.69 (0.59 to 0.80) 2.32E-06  777/1499 691/1403 0.453
rs6972219 7  IGFBP1 T  45/1299  20/1960 3.39 (2.00 to 5.78) 1.77E-06   42/2206  20/1960 0.0205
rs2173035 7  IGFBP1 A  47/1303  21/1957 3.36 (2.00 to 5.65) 1.27E-06   50/2198  21/1957 0.0033
rs6956740 7  IGFBP1 T  48/1294  21/1973 3.49 (2.08 to 5.85) 5.12E-07   49/2217  21/1973 0.0045
rs3807306 7  IRF5 T 785/555 974/992 1.44 (1.25 to 1.66) 3.15E-07 1199/1051 974/992 0.0152
 All frequencies were evaluated from the real genotyping data. 
 *Same direction for association in RA subgroups. 
 † Cochran–Armitage trend test. 
 ACPA, antibodies to citrullinated peptide antigens; GWAS, genome-wide association studies; RA, rheumatoid arthritis; SNP, single nucleotide polymorphism. 
 Figure 3  Quintile-quintile probability plots for observed versus expected distribution of p values for χ 2 statistics for (A) ACPA-negative RA versus controls 
and (B) ACPA-positive RA versus controls. ACPA, antibodies to citrullinated peptide antigens; RA, rheumatoid arthritis; SNP, single nucleotide polymorphism. 
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 Contrasts between ACPA-positive and ACPA-negative RA 
 To formally test the hypothesis of a contrast between the two 
disease subgroups, we used the EIRA study to perform a direct 
comparison between ACPA-positive and ACPA-negative RA 
using the full GWAS data sets for these two populations of RA 
patients. The threshold for genome-wide signifi cance was esti-
mated as 2.9 × 10 −8 (after Bonferroni correction for 1 723 056 
tests). After corrections for multiple testing we found signifi cant 
differences only in the HLA region of chromosome 6p with 814 
SNPs spanning between 31 278 893 and 33 164 413 (see table 4 
in online supplement). When we increased the threshold to 10 −5 
we identifi ed an additional 352 SNPs in the HLA region tar-
geted to physical positions in the extended HLA locus between 
30 155 944 and 33 886 942 (3 730 998 bp) and three additional 
non-HLA SNPs ( table 2 ): rs4305317 from chromosome 2 close to 
the  LDHAL3 (lactate dehydrogenase A-like 3) gene, rs6448119 
from chromosome 4 between the  KCNIP4 (Kv channel inter-
acting protein 4) and the  GPR125 (G protein-coupled receptor 
 We subsequently extended the observations on patients with 
ACPA-positive RA in EIRA with a replication in NARAC using 
patients with ACPA-positive RA as cases and healthy indi-
viduals from a New York cancer surveillance study as controls. 
Many of the SNPs in the HLA region and one PTPN22 SNP 
(rs2476601) from EIRA were well replicated in NARAC (see 
table 3 in online supplement). 
 We also made an extra validation against the WTCCC study 
where, however, we were not able to separate patients based 
on ACPA status. It is known, however, that the large majority 
of the WTCCC RA cohort is rheumatoid factor (RF)-positive 
and, owing to a high correlation between RF and ACPA status, 
it most likely dominated by ACPA-positive RA cases.  28  Many of 
the SNPs in the HLA region and one PTPN22 SNP (rs2476601) 
were well replicated also in WTCCC (table 3 in online supple-
ment) with an overall OR for rs2476601in the three studies of 
1.74 (95% CI 1.59 to 1.90, p=2.73045E-36, Mantel–Haenszel χ 2 
test for 17 520 chromosomes). 
 Figure 4  Probability plot for association with ACPA-positive rheumatoid arthritis (1147 cases) versus 1079 controls, λ GC = 1.0263 based on 
1 723 056 single nucleotide polymorphisms (SNPs). Upper fi gure represents data for all SNPs including MHC locus and lower fi gure is without data for 
SNPs from MHC locus. ACPA, antibodies to citrullinated peptide antigens. 
 Figure 5  Probability plot for association for ACPA-positive RA (1147 cases) versus ACPA-negative RA (774 cases). λ GC = 1.0029 based on 
1 723 056 single nucleotide polymorphisms. ACPA, antibodies to citrullinated peptide antigens; RA, rheumatoid arthritis. 
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125) genes, and rs2961663 from chromosome 5 in the  GMCL1L 
(germ cell-less homolog 1) gene. 
 The described differences in the HLA region between ACPA-
positive and ACPA-negative disease are well in line with a previ-
ously published dataset on ACPA-positive and ACPA-negative 
patients with RA compared with controls which was focused 
only on the HLA using another set of SNPs together with classi-
cal PCR-based HLA-typing.  7    32  
 Since the difference in allelic frequency in this analysis could 
be linked to the effect from any of the RA subgroups although it 
is dominated by susceptibility risk alleles for ACPA-positive RA, 
it is interesting to note that the two non-HLA SNPs rs4305317 
and rs6448119 seem to be in association primarily with ACPA-
negative RA. 
 DISCUSSION 
 We report the fi rst GWAS in one of the major subsets of RA 
defi ned by absence of ACPA reactivity, and the fi rst comparison 
of GWAS results between ACPA-positive and ACPA-negative 
RA. Overall, we found signifi cant differences in genetic associa-
tions between the two subsets, both concerning genes already 
described as being associated with ACPA-positive RA in previ-
ous genome-wide studies and concerning tentative associations 
that are preferentially seen for the ACPA-negative subset of RA. 
Notably, only very few genetic variations were associated with 
both RA subsets and those had a very minor infl uence on the 
genetic risk of RA. 
 The contrasting genetic aetiologies of ACPA-positive and 
ACPA-negative RA are most starkly evident at the HLA locus, 
and these data are in line with previous studies that were spe-
cifi cally focused on the HLA region and used other SNPs and 
smaller numbers than in the present study.  7    32  These data there-
fore show that the functional conclusions concerning molecular 
pathogenesis of arthritis that have since long been deduced from 
the association with HLA genes, and particularly with variations 
in HLA class II genes, are valid only for the ACPA-positive sub-
set of the disease; the implications of this discrepancy have also 
been discussed previously on the basis of data from classical 
PCR-based HLA genotyping.  7    9    25    32  
 Concerning the non-HLA genes, several studies have now 
been published describing variations associated with either 
ACPA-positive RA  13    14    17    27  or with RA where no discrimination 
between the two subsets was made.  28  When analysing the pub-
lished genetic variations that showed genome-wide or sugges-
tive associations with ACPA-positive disease or with the entire 
RA population and also with the ACPA-negative RA subset in 
the EIRA study, the genetic variants in association with ACPA-
positive RA were most often not signifi cant for ACPA-negative 
RA and vice versa. 
 We performed an analysis of 14 well-established variations 
for association with ACPA-positive RA in combined material 
from Sweden, the USA and the UK and for ACPA-negative RA 
in the Swedish EIRA cohort ( table 3 ). As can be seen from this 
analysis, most previously detected genetic variations (9/14) 
were associated only with ACPA-positive RA, three appeared 
to be associated with both subgroups, one appeared to be spe-
cifi c for ACPA-negative disease and one appeared to provide 
opposite results in the two subgroups. Since most efforts in 
the genetics of RA have been devoted to ACPA-positive RA, 
this difference may be due to selection rather than to a true 
absence of association with ACPA-negative RA. A recent twin 
study of ACPA-negative RA indicated that this phenotype is 
also genetically predetermined.  33  Thus, our present negative 
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results have to be interpreted with caution given the limited 
power of our investigations. Nevertheless, we can be confi dent 
that the major discrepancies described by GWAS—that is, the 
differential associations in the HLA region—are indeed true 
differences between the ACPA-positive and ACPA-negative 
RA subsets. 
 Concerning the non-HLA genes associated with the different 
subsets of RA, we performed additional genotyping to confi rm 
the accuracy of imputation of SNPs using real genotyping data, 
when possible, to evaluate differences between the two RA sub-
sets in order to decrease the risk of false positive fi ndings due to 
use of imputations. Using this methodology we were not able 
to identify any strong genetic risk factors for ACPA-negative 
RA, while a number of SNPs from the HLA region as well as 
non-HLA SNPs were in association with ACPA-positive  disease, 
confi rming previously published data for ACPA-positive RA.  13    28  
Thus, although we cannot totally exclude overlapping genetic 
risk factors for the two RA subgroups, it is unlikely that this 
overlap is very big. We can also confi rm the major differences 
between ACPA-positive and ACPA-negative RA concerning 
linkage to the HLA region. 
 Deciphering the pathogenesis of ACPA-negative RA remains 
a major challenge for genetic studies. In this study we found 
suggestive evidence—but not genome-wide signifi cance-based 
evidence—for two new candidate loci in ACPA-negative disease 
(ie, RPS12P4 and IGFBP1). We also found suggestive evidence 
for the previously described IRF5 locus as susceptibility genes 
for ACPA-negative RA. Thus, most of the difference in genetic 
factors between ACPA-negative and ACPA-positive RA is seen 
in the HLA region, close to the HLA-DRB1 locus. The non-HLA 
variant rs4305317, close to RPS12P4 at chromosome 2, is the 
best candidate for association with ACPA-negative RA but not 
with ACPA-positive RA. It should be emphasised, however, that 
this association as well as other data related to associations with 
ACPA-negative RA need independent replication owing to the 
limited size of the present study. 
 GWAS provide new potentials to determine genetic vari-
ations and molecular pathways that are shared between 
different infl ammatory diseases. The associations of sev-
eral diseases and disease subsets with PTPN22, CD40, 
TRAF1-C5 and STAT4 are typical examples of this sharing.  17  
  27    34    35  The present study illustrates the other complementary 
 perspective—namely, the potential also to use GWAS to sub-
divide criterion-based diseases such as RA into new entities. 
As exemplifi ed here, one subset of a disease may then share 
certain risk genes and possibly pathogenic pathways with 
some other autoimmune entities, as is the case for PTPN22 
and ACPA-positive RA and type I diabetes,  36  whereas the 
other subset of the same criterion-based disease may share 
genetic linkages and pathogenetic pathways with still other 
autoimmune entities. We can expect refi ned classifi cations of 
criterion-based diseases such as RA to lead to the use of genet-
ics to provide an indication of what molecular pathways are 
involved in the pathogenesis of different subsets of today’s 
criterion-based diseases. This knowledge should, in turn, be 
indispensable when trying to fi nd treatments to target these 
pathways in patients in these different and distinct subsets of 
chronic autoimmune diseases. 
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 Table 3  Frequencies of previously detected genetic variants for RA: comparison of meta-analysis of ACPA-positive RA patients from three 
populations with ACPA-negative RA patients 
 SNP  Chromosome  Gene/loci 
 Minor 
allele* 
 EIRA ACPA-
positive 
 EIRA ACPA-
negative  NARAC  WTCCC  ACPA-positive RA  ACPA-negative RA 
 MAF 
cases 
 MAF 
controls 
 MAF 
cases 
 MAF 
controls 
 MAF 
cases 
 MAF 
controls 
 MAF 
cases 
 MAF 
controls  OR (95%CI)*  OR (95%CI)† 
rs3890745 1p36  MMEL1-
TNFRSF14 
C 0.28 0.31 0.29 0.31 0.29 0.32 0.29 0.34  0.85 (0.80 to 0.91) 0.94 (0.82 to 1.09)
rs2476601 1p13  PTPN22 A 0.18 0.12 0.14 0.12 0.16 0.08 0.15 0.09  1.74 (1.59 to 1.90) 1.17 (0.96 to 1.42)
rs7574865 2q32  STAT4 T 0.24 0.22 0.26 0.22 0.25 0.23 0.23 0.21  1.12 (1.05 to 1.21)  1.23 (1.05 to 1.43) 
rs3087243 2q33  CTLA4 A 0.34 0.39 0.38 0.39 0.38 0.42 0.43 0.45  0.88 (0.83 to 0.93) 0.97 (0.84 to 1.11)
rs2064476 6p21  HLA-DPB1 G 0.20 0.26 0.27 0.26 0.22 0.30 0.25 0.31  0.71 (0.66 to 0.76) 1.02 (0.88 to 1.18)
rs10499194 6q23  OLIG3 , TNFAIP3 T 0.19 0.21 0.20 0.21 0.25 0.30 0.25 0.27  0.86 (0.80 to 0.92)  1.28 (1.10 to 1.50) 
rs6920220 6q23  OLIG3 , TNFAIP3 A 0.25 0.23 0.24 0.23 0.24 0.19 0.26 0.22  1.22 (1.14 to 1.31) 1.08 (0.93 to 1.26)
rs3807306 7q32  IRF5 G 0.45 0.49 0.41 0.49 0.48 0.50 0.46 0.50  0.87 (0.81 to 0.92)  0.72 (0.63 to 0.82) 
rs2812378 9p13  CCL21 G 0.35 0.32 0.36 0.32 0.35 0.33 0.37 0.34  1.14 (1.07 to 1.21)  1.21 (1.05 to 1.39) 
rs3761847 9q33  TRAF1-C5 G 0.51 0.46 0.48 0.46 0.47 0.38 0.43 0.43  1.32 (1.21 to 1.44)‡ 1.08 (0.95 to 1.23)
rs4750316 10p15  PRKCQ C 0.17 0.21 0.19 0.21 0.18 0.19 0.16 0.20  0.83 (0.77 to 0.90) 0.87 (0.74 to 1.03)
rs1678542 12q13  KIF5A - PIP4K2C G 0.40 0.42 0.42 0.42 0.36 0.37 0.33 0.37  0.88 (0.82 to 0.93) 0.99 (0.87 to 1.14)
rs1328674 13q14-q21  HTR2A T 0.04 0.02 0.04 0.02 0.04 0.04 0.04 0.04 1.16 (0.99 to 1.35)  1.83 (1.25 to 2.68) 
rs4810485 20q13  CD40 T 0.20 0.24 0.24 0.24 0.21 0.27 0.23 0.24  0.77 (0.69 to 0.85)‡ 0.98 (0.84 to 1.14)
Statistically signifi cant odds ratios shown in bold.
 *Mantel–Haenszel OR from meta-analysis of EIRA ACPA-positive RA/NARAC/WTCCC. 
 †Mantel–Haenszel OR for EIRA ACPA-negative RA. 
 ‡WTCCC excluded due to heterogeneity between ACPA positive cohorts. 
 ACPA, antibodies to citrullinated peptide antigens; EIRA, Swedish Epidemiological Investigation of Rheumatoid Arthritis; MAF, minor allele frequency; NARAC, North American RA 
Consortium; RA, rheumatoid arthritis; SNP, single nucleotide polymorphism; WTCCC, Wellcome Trust Case–Control Consortium. 
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